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Abstract
Background: The AIDS epidemic in Brazil remains concentrated in populations with high vulnerability to HIV infection, and
the development of an HIV vaccine could make an important contribution to prevention. This study modeled the HIV
epidemic and estimated the potential impact of an HIV vaccine on the number of new infections, deaths due to AIDS and
the number of people receiving ARV treatment, under various scenarios.
Methods and Findings: The historical HIV prevalence was modeled using Spectrum and projections were made from 2010
to 2050 to study the impact of an HIV vaccine with 40% to 70% efficacy, and 80% coverage of adult population, specific
groups such as MSM, IDU, commercial sex workers and their partners, and 15 year olds. The possibility of disinhibition after
vaccination, neglecting medium- and high-risk groups, and a disease-modifying vaccine were also considered. The number
of new infections and deaths were reduced by 73% and 30%, respectively, by 2050, when 80% of adult population aged 15–
49 was vaccinated with a 40% efficacy vaccine. Vaccinating medium- and high-risk groups reduced new infections by 52%
and deaths by 21%. A vaccine with 70% efficacy produced a great decline in new infections and deaths. Neglecting
medium- and high-risk population groups as well as disinhibition of vaccinated population reduced the impact or even
increased the number of new infections. Disease-modifying vaccine also contributed to reducing AIDS deaths, the need for
ART and new HIV infections.
Conclusions: Even in a country with a concentrated epidemic and high levels of ARV coverage, such as Brazil, moderate
efficacy vaccines as part of a comprehensive package of treatment and prevention could have a major impact on preventing
new HIV infections and AIDS deaths, as well as reducing the number of people on ARV. Targeted vaccination strategies may
be highly effective and cost-beneficial.
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Introduction
After 30 years the AIDS pandemic continues to compromise the
health, quality of life and productivity of populations, and
significantly affects economies as well as societal and family
structures. Although the epidemic in Brazil remains concentrated
amongst populations with increased vulnerability to HIV infection
[1], more than 500,000 AIDS cases and 200,000 AIDS deaths
have been reported by 2008 [2].
To address the challenge of continued HIV transmission as well
as increasing treatment needs, the Brazilian government has
prioritized prevention efforts [3–4], and has implemented a broad
treatment and care program throughout the five geographical
regions in the country. The treatment program is based on
technical guidelines determined by a national expert committee,
which ensures that all patients living with HIV and AIDS in need
of antiretroviral (ARV) treatment have access to state-of-the-art
care, including options for patients resistant to first and second line
regimens [5].
While much has been achieved with the adoption of existing
preventive measures and the introduction of potent drugs that
severely reduce viral load, there is still a pressing need to develop
additional prevention options, such as HIV vaccines, to drastically
reduce the number of new infections. A number of studies have
been published that involve the application of mathematical
modeling to questions of the potential impact of an HIV vaccine
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(see [6] for a review of this literature). These studies have generally
shown that even a moderate-efficacy vaccine could have a
significant impact in reducing new HIV infections and could
represent a vital strategy to control the epidemic. Recent
mathematical model studies have shown that a moderately
effective vaccine given to the adult population could reduce future
HIV prevalence in low- and middle- income countries by 30% to
35% in 10 to 15 years [7–8].
Considering the specificities of the AIDS epidemic in Brazil, this
study was undertaken to model the Brazilian epidemic and to
estimate the potential impact of an HIV vaccine on the number of
new infections, deaths due to AIDS and the number of people
receiving antiretroviral (ARV) treatment, under various scenarios.
Methods
The Spectrum HIV Vaccine Module [9] was used to model the
historical prevalence of HIV in Brazil from 1975 to 2010 and the
impact of an HIV vaccine on the future course of the epidemic.
Details of the model structure and key assumptions are available
elsewhere [10]. The model divides the sexually active population
aged 15–49 by sex and risk group. Although some infections occur
at ages above 50, the percentage is small, less than 10%, and most
behavioral indicators refer to the 15–49 age group. The risk
groups are injecting drug users, men who have sex with men, high
risk heterosexuals (female sex workers and their male clients),
medium risk heterosexuals (men and women with more than one
partner in the last year) and low risk heterosexuals (men and
women with only one partner in the last year). The probability of
acquiring a new HIV infection is determined by characteristics of
the index person (number of partners), the partner (HIV status,
stage of infection, ART use), and the partnership (sex acts per
partner, condom use, STI prevalence, heterosexual or MSM
contact, male circumcision status). Infected persons progress
through a primary stage of infection with high infectivity, an
asymptomatic stage with low infectivity, a symptomatic stage with
high infectivity, to AIDS death. Infectivity is reduced by ARV use.
The model includes a component to estimate the effects of
prevention interventions on key behaviors (condom use, number of
partners, unsafe injecting behavior) based on a summary of the
impact literature [11].
The model was set up for Brazil using behavioral data from
surveys [12–22], epidemiological [2,23] and ART data [24] from
the Brazilian Ministry of Health (MOH). We calibrated the model
to HIV prevalence data by risk group and validated it by comparing
the estimated AIDS mortality, HIV prevalence and the number of
people receiving ARV with respective data from the MOH [2,23–
24]. Although there are no official estimates of incidence to which
the model results can be compared, the number of new infections
estimate is a consequence of matching official estimates of mortality
and prevalence. The parameter [25–28] and behavioral values used
[12–22] are shown in Tables 1 and 2.
The HIV vaccine module can be used to examine the effects of
vaccines with difference characteristics: reduction in susceptibility,
disease progression and/or infectiousness, duration of effectiveness
and take or degree type of action. Vaccination programs can be
defined in terms of coverage over time of the entire adult
population or targeted coverage for specific population groups.
The impacts of vaccines with different characteristics and the
impacts of different implementation strategies were explored
under a variety of different assumptions. In this paper, we present
the results for a vaccine introduced in 2015 and with 80%
coverage reached by 2020, with duration of 20 years. We assume
that an HIV test is not a requirement for vaccination. ART
coverage is nearly universal in Brazil today and we assumed that
would continue in all projections.
Table 1. Parameter Values used to Simulate the Brazilian HIV
Epidemic.
Parameter Value Source
Relative infectiousness compared to
asymptomatic stage
Pilcher [25]
Primary stage 8
Symptomatic stage 4
Probability of HIV transmission per act,
heterosexual contact
0.0007 Powers [26]
Transmission multiplier for MSM contacts 2.6 Vittinghoff [27]
Duration of (in years): Fitted
Asymptomatic stage 10
Symptomatic stage 3
Condom efficacy 0.8 Weller [28]
Annual survival on ART 0.95
doi:10.1371/journal.pone.0011736.t001
Table 2. Current Behaviors used to Simulate the Brazilian HIV Epidemic, 2007.
Risk groups
Not sexually active Low Medium High MSM IDU
Population distribution (%)
Males 6.5 66.5 18.2 4.5 3.5 0.8
Females 15.3 78.8 4.6 0.9 - 0.4
Condom use (%) 7 16 52 80
Partners #
Males 1 3 10 4
Females 1 3 75 -
Sex acts per partner # 70 40 5 25
Source [12–22].
doi:10.1371/journal.pone.0011736.t002
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and 70% effective preventive ‘‘take’’ vaccine, which reduces both
susceptibility and transmission. A ‘‘take’’ vaccine is one that
achieves an efficacy of 50%, for example, by completely protecting
50% of those vaccinated and providing no protection for the other
50%, as opposed to a ‘‘degree’’ vaccine that achieves 50% efficacy
by reducing susceptibility by 50% in all those vaccinated.
This study also looked at the potential impact of diverse
vaccination strategies, including vaccinating the general adult
population, aged 15–49 (including high risk populations); vacci-
nating 15-year-old adolescents; and vaccinating medium- and
high-risk groups, defined as men who have sex with men (MSM),
injecting drug users (IDU), and commercial sex workers and their
partners (considered here as medium- and high-risk behavior
heterosexuals).
In addition, a vaccine scenario that models the potential impact
of a disease-modifying vaccine, defined as a vaccine that reduces
infectiousness and delays progression to the development of AIDS,
and consequently slows the progression to AIDS death, or, in
other words, that would not affect individual susceptibility to HIV
infection but instead reduces infectiousness and lengthens the
amount of time spent in the asymptomatic phase by reducing viral
load, was explored.
To assess the potential effect of behavioral disinhibition on the
trajectory of Brazil’s epidemic in the presence of an AIDS vaccine,
vaccine impact scenarios were explored in which a 50% decline in
condom use was considered either immediately after vaccine
introduction or more gradually over time. To further explore the
effectiveness of targeted vaccination strategies, the study also
modeled the impact of failure to reach the medium- and high-risk
population groups, by vaccinating 20% of these groups while
reaching 80% of low-risk adult population aged 15–49.
Results
The model consistency can be seen in Figures 1 and 2. As can
be observed, the progression of AIDS deaths over time adequately
reflects the history of the epidemic in Brazil (Figure 1). Spectrum
estimated 182,562 cumulative AIDS deaths for those aged 15–49,
12.3% more deaths when compared with 162,545 deaths reported
by the Brazilian Mortality Information System for the period
1985–2007. When comparing the number of people receiving
ARV, the Spectrum estimates were also similar to the official data,
which report about 190,000 on ARV by the end of 2008 (Figure 2).
The HIV prevalence estimated by Spectrum was slightly lower
(0.40%) in 2004, when compared to a 68% confidence interval
from the official estimate (0.44%–0.77%).
In order to capture the longer- term impact of an HIV vaccine,
we simulated the epidemic to 2050. Spectrum projects 1.1 million
new infections and 468,000 deaths from 2010 to 2050, keeping
HIV prevalence relatively stable around 0.42 in the absence of a
vaccine or changes in preventive measures and in patient
treatment coverage.
Scenarios to study the impact of an HIV vaccine in the
Brazilian epidemic
Compared with a baseline scenario with no vaccine, vaccinating
80% of the adult population with a 40% efficacy vaccine reduced
the cumulative number of new HIV infections from 2020–2050 by
73%(Figure 3)andAIDSdeathsby30%(Figure 4).Vaccinatingthe
medium- and high-risk behaviorpopulationresulted inanestimated
52% reduction in new infections (Figure 3) and 21% reduction in
AIDS deaths (Figure 4). However, the smallest impact was observed
when vaccination strategies targeted only adolescents.
A 70% effective vaccine given to the general population would
result in a significantly greater impact, interfering dramatically in
the Brazilian epidemic by reducing the number of new infections
from 2020 to 2050 by 92%. Even a targeted strategy of vaccinating
only medium- and high-risk behavior population groups with a
70% effective vaccine would still produce dramatic results,
reducing new infections by 74%.
A disease-modifying vaccine scenario
When the general population was vaccinated with a disease-
modifying vaccine, the cumulative number of new infections
was reduced by 46% (Figure 5) and the number of deaths had a
30% reduction (Figure 6) from 2020 to 2050. A lower impact
was observed when only specific groups were targeted for
vaccination.
Figure 1. AIDS deaths model fit. Number of AIDS deaths and model fit. Brazil, 1985–2007. The blue line, deaths for age group 15–49 as reported
by the Brazilian National Mortality Information System; the red line, Spectrum estimates of number of AIDS deaths in the same age group.
doi:10.1371/journal.pone.0011736.g001
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reducing the number of patients receiving ARV, although not as
effective as preventive vaccines (Figure 7).
Assessment of the relative impact of targeted
vaccination strategies
With the understanding that public health officials will consider
vaccination strategies not only on the basis of their overall impact,
but also taking into account dose availability at the time of
licensing, cost of the vaccine and highest impact in relation to
investment, the study explored how the different vaccine strategies
compared in terms of impact and the number of doses required for
each strategy. Table 3 summarizes the vaccine efficacy, the
percentage reduction, the cumulative number of new HIV
infections averted, the number of doses required and the number
of HIV infections averted per 100,000 vaccinations, according to
population vaccinated from 2020 to 2050, for both preventive and
disease-modifying vaccines. With 80% coverage, the highest
reduction in the number of new infections is reached if the
general population aged 15–49 is vaccinated, although requiring a
very high number of vaccine doses. On the other hand, the better
result in terms of number of new infections averted per 100,000
doses is obtained when medium- and high-risk behavior popula-
tion groups are prioritized for vaccination, with 4 times more
Figure 2. ARV patients and model fit. Number of patients receiving ARV and model fit. Brazil, 1999–2007. The blue line, number of patients of all
age reported by the Brazilian STD, AIDS and Viral Hepatitis Department; the red line, Spectrum estimates of number of patients receiving ARV aged
15–49.
doi:10.1371/journal.pone.0011736.g002
Figure 3. HIV vaccine impact on new infections. Number of estimated new HIV infections according to population vaccinated by year. Red line,
baseline projection in the absence of a vaccine; green line, vaccination of adolescents (15 years old); purple line, vaccination of specific population:
MSM, IDU, medium- and high-risk heterosexuals; blue line, vaccination of adults aged 15–49.
doi:10.1371/journal.pone.0011736.g003
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population (Table 3).
Behavior reversal (disinhibition) and failure to reach
medium- and high-risk behavior population groups
A few additional scenarios were considered to assess the
relevance of factors that may reduce or interfere with the impact
of a vaccine, such as lack of effective education and counseling of
vaccine recipients, leading to behavior disinhibition, and failure to
reach and vaccinate populations at higher risk. Two scenarios
were considered to look into the potential importance of behavior
disinhibition. In the first scenario, the number of new infections
was reduced by 42% (42% instead of 73%) when the general
population was vaccinated with a low-efficacy vaccine and
gradually reduced condom use. In the second analysis regarding
behavior dishinibition, the study observed an 8.5% increase in the
cumulated number of new HIV infections when 50% of the
medium- and high-risk behavior vaccinated population immedi-
ately stopped using condoms (Figure 8). This remains true even
with a more effective vaccine (Figure 9).
The analysis shows that the most effective strategies are those
that target vaccinations to medium- and high-risk groups, as seen
by the number of infections averted per 100,000 people vaccinated
in Table 3. To demonstrate the importance of ensuring adequate
coverage of high-risk individuals, the study explored the impact of
reaching 80% vaccination coverage among the low-risk adult
Figure 4. HIV vaccine impact on AIDS deaths. Number of estimated AIDS deaths according to population vaccinated by year. Red line, baseline
projection in the absence of a vaccine; green line, vaccination of adolescents (15 years old); purple line, vaccination of specific population: MSM, IDU,
medium- and high-risk heterosexuals; blue line, vaccination of adults aged 15–49.
doi:10.1371/journal.pone.0011736.g004
Figures 5. Impact of disease-modifying vaccine on number of new HIV infections. Number of new HIV infections according to population
vaccinated with a disease-modifying vaccine. Red line, baseline projection in the absence of a vaccine; blue line, vaccination of adults aged 15–49;
purple line, vaccination of specific population: MSM, IDU, medium- and high-risk heterosexuals.
doi:10.1371/journal.pone.0011736.g005
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behavior groups in the vaccinated cohort. This scenario was
shown to prevent 29% fewer new HIV infections (52% compared
to 73%) when compared to a vaccination strategy that also
includes the medium- and high-risk population groups (Figure 10).
Discussion
Although the development of an effective HIV vaccine is still
years away, modeling studies such as this one are relevant and
critical to preparing governments for adopting appropriate
policies when a vaccine becomes available [8,29] or as a vaccine
candidate advances into later stages of clinical testing. Mathe-
matical modeling and computer simulation are powerful tools for
health policy evaluation, policy dialogue, and advocacy efforts
[8–9,30–31].
Spectrum was able to effectively model the Brazilian epidemic,
producing projections of the number of new infections, AIDS
deaths and people needing ARV based on various vaccine profiles
and vaccination strategies. This exercise has shown that, even in a
country like Brazil with a concentrated epidemic and ample
availability of treatment and services for people with HIV and
AIDS, a partially-effective vaccine could significantly reduce the
number of new HIV infections and the future need for treatment,
as well as the deaths caused by AIDS.
A unique aspect of this modeling application is that the
epidemiological model was validated by comparing estimates of
AIDS deaths for the period 1985 to 2007 with those reported by
Figure 6. Impact of disease-modifying vaccine on number of AIDS deaths. Number of AIDS deaths according to population vaccinated with
a disease-modifying vaccine. Red line, baseline projection in the absence of a vaccine; blue line, vaccination of adults aged 15–49; purple line,
vaccination of specific population: MSM, IDU, medium- and high-risk heterosexuals.
doi:10.1371/journal.pone.0011736.g006
Figure 7. Patients on ARV. Estimated number of patients receiving ARV according to type of vaccine by year. Red line, baseline projection in the
absence of a vaccine; blue line, 40% efficacy preventive vaccine; green line, 100% disease-modifying vaccine with 40% reduction in infectiousness.
doi:10.1371/journal.pone.0011736.g007
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rapid decline in AIDS deaths after the introduction of ART. It is
possible that all AIDS deaths were not reported and that Spectrum
has overestimated the AIDS deaths in Brazil. However, several
studies have shown that the Brazilian Mortality System is quite
reliable in terms of completeness and accuracy, as well as in
relation to cause of death [32–33].
In the base projection, the annual number of new infections
increases somewhat from 2010 to 2020 largely due to an increase
among IDU, required to maintain constant prevalence after a
period of declining prevalence among that group. A projection of a
constant number of new HIV infections among IDU may be
equally likely but, in either case, this assumption has little effect on
the major conclusions. Also, the base projection without a vaccine
shows a slight rise in the number of AIDS deaths. This is due to
increasing mortality among those who have been on ART since
the rapid scale-up of ART coverage in the 1990s.
Even though the model replicates the historical trends in
Brazil, there is no guarantee that the model is correct in all
aspects. With so many factors influencing model behavior it is
likely that there are other sets of parameters and behavioral
values that would fit the historical trends equally well. The impact
of vaccines might be different with these other configurations.
Advanced modeling techniques can be used to explore the
impacts in the complete parameter space [34–35] but we have
not done that here.
The impact analysis focuses on the period after 2020 when 80%
coverage is reached and the impact of the vaccine is most
significant. This relatively high coverage rate was deemed realistic
by the project’s steering committee - formed by Brazilian advisors
with thorough understanding of the national epidemic - because of
Brazil’s relatively strong health infrastructure and successful
coverage of existing health technologies, such as currently licensed
vaccines and ARVs.
Efficacies of 40% and 70% were chose to represent a plausible
range of likely vaccines that might be used in national programs.
While a vaccine with efficacy greater than 70% would certainly be
desirable, the difficulties to date in developing an effective vaccine
indicates that the first vaccines to become available are not likely to
provide perfect protection. Vaccines with efficacies below 30–40%
are not likely to become approved for widespread use given the
possibilities of risk compensation leading to perverse results. The
recently completed RV144 vaccine trial indicated efficacy of around
30% [36]. These results are being used to guide future research
rather than supporting immediate introduction of the tested vaccine.
A vaccine with 40% effectiveness given to 80% of the population
would reduce susceptibility by 32% (40% times 80%), but the long-
term effect is much larger, 72% from 2020 to 2050. The reason is
that the reduction in susceptibility leads to fewer new infections
which, in turn leads to lower prevalence. Thus in the future the
susceptible population not only has reduced susceptibility to
infection but also faces a reduced risk of encountering and infected
partner. Over the long-term these secondary effects can be as large
or larger than the reduction in susceptibility.
The analysis presented here has shown that vaccinating the
adult population achieved the largest reduction of new HIV
infections and deaths compared to other strategies. However,
vaccinating specific population groups, such as those with higher-
risk behavior, produced a greater impact with fewer vaccine doses
required, which is important to note in resource-constrained
environments. Through the use of targeted strategies, a significant
proportion of the groups at increased risk for HIV can be reached
with a smaller number of vaccinations than those required for
vaccinating the adult population. For this reason, it is likely that a
Table 3. Vaccination Strategies.
Population to be vaccinated
New HIV
infections (#)
Reduction in new
infections (%)*
Infections
averted (#)
Doses of
vaccine required
(per 1 million)
Infections averted per
100,000 vaccinations (#)
Preventive Vaccine/Vaccine efficacy (%)
Adults (aged 15–49)
40 230203 72.8 617647 241 256
70 72369 91.5 775481 241 322
Medium- & High-risk behavior groups
40 405639 52.2 442211 43 1023
70 222754 73.7 625096 43 1447
15-year-olds
40 725383 14.4 122467 43 283
70 643471 24.1 204379 43 472
Adults, excluding medium- and high- risk behavior groups
40 408880 51.8 438970 208 211
70 214547 74.7 633303 208 304
Disease-Modifying Vaccine
Adults (aged 15–49) 458773 45.9 389077 241 161
Medium- & High-risk behavior groups 767485 9.5 80365 43 186
Vaccine efficacy, cumulative number of new HIV infections, percentage reduction in relation to a no vaccine scenario, cumulative number of new HIV infections averted,
number of doses required, and number of infections averted per 100,000 population vaccinated according to population to be vaccinated and type of vaccine
(preventive or disease modifying).
*Compared to No Vaccine Scenario, where 847,850 new HIV infections would occur from 2020 to 2050 in the absence of vaccination.
doi:10.1371/journal.pone.0011736.t003
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would likely be more cost-effective, with a higher number of
infections averted per vaccination. However, it is crucial that
vaccination strategies for the adult population be designed to reach
groups at greater risk, ensuring that these groups have equal access
to the vaccine. Vaccinating only individuals at lower risk for HIV
would significantly diminish the impact of the vaccine, compro-
mising the goal of controlling the epidemic.
One concern with regards to implementing partially efficacious
vaccines is the issue of behavioral disinhibition, which occurs when
vaccinated individuals believe they are protected from HIV
infection and therefore increase the behaviors that put them at
greater risk of exposure to HIV [6]. Several studies have described
how behavioral reversals could mitigate the gains from vaccination
or even produce perverse outcomes where the use of the vaccine
results in more infections [8,37–39]. This study reinforces those
findings. Even in a country with a concentrated epidemic,
disinhibition will be a great challenge with the potential to negate
the impact of a partially efficacious HIV vaccine. Efforts should be
made to keep adherence to preventive measures at a high level,
especially among populations at greater risk of infection, even
when an HIV vaccine becomes available.
Figure 8. Impact of disinhibition with 40% efficacy vaccine. Number of new HIV infections estimates with a 40% efficacy vaccine and
presence of disinhibition. Red line, baseline projection in the absence of a vaccine; blue line, vaccination of adults aged 15–49; brown line, vaccination
of adults aged 15–49 with gradual disinhibition; purple line, vaccination of adults aged 15–49 with instantaneous disinhibition; green line, vaccination
of specific population (MSM, IDU, medium- and high-risk heterosexuals) with instantaneous disinhibition.
doi:10.1371/journal.pone.0011736.g008
Figure 9. Impact of disinhibition with 70% efficacy vaccine. Number of new HIV infections estimates with a 70% efficacy vaccine and
presence of disinhibition. Red line, baseline projection in the absence of a vaccine; blue line, vaccination of adults aged 15–49; purple line, vaccination
of adults aged 15–49 with instantaneous disinhibition.
doi:10.1371/journal.pone.0011736.g009
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a greater impact on the course of the epidemic, it is important to
stress the potential benefits of a disease-modifying vaccine. This
modeling exercise has demonstrated that such a vaccine could
reduce AIDS deaths and also substantially decreases the demand
for ARV immediately after introduction. A disease-modifying
vaccine would also reduce infectiousness, further contributing to
control the epidemic [40–42]. Without a reduction in infectious-
ness, disease-modifying vaccines would likely lead to more
infections [40–41,43–44] but fewer deaths [40,44]. This study
did not investigate the impact of a vaccine in either the absence of
or reduction in ARV coverage because Brazil has a governmental
policy to provide treatment to all in need.
The potential impact of even a moderate-efficacy vaccine as
indicated in this study can also provide a powerful argument for
the relevance of continued investment in research and develop-
ment towards a vaccine as it presents evidence of how efforts to
control HIV would dramatically benefit from it, even in the
context of concentrated epidemics. For middle-income countries
such as Brazil that have well established scientific and technolo-
gical capacity, the results of this study, which highlight the
relevance of a vaccine for the Brazilian epidemic, as well as others
with same characteristics, should stimulate the implementation of
more effective policies to promote and facilitate research in this
field. Moreover, conclusions of the study related to the relative
impact of vaccination strategies may prove particularly relevant in
informing and accelerating discussions around vaccine introduc-
tion and delivery encouraging rapid adoption of a future product.
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